NCT06555796 - Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

December 21, 2026

Study Completion Date

June 21, 2029

Conditions

Prostate CancerHigh-risk Biochemical RecurrenceHigh Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate CancerNon-metastatic Castration-sensitive Prostate Cancer

Interventions

DRUG

Xaluritamig

IV infusion

Trial Locations (10)

2050

RECRUITING

Chris OBrien Lifehouse, Camperdown

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

3144

RECRUITING

Cabrini Hospital, Malvern

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

28204

RECRUITING

Levine Cancer Institute, Charlotte

55455

RECRUITING

University of Minnesota Medical Center Fairview, Minneapolis

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

97239

RECRUITING

Oregon Health and Science University, Portland

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle